Blockchain Registration Transaction Record

Mainz BioMed Seeks FDA Breakthrough Device Designation for Advanced Colorectal Cancer Test

Mainz BioMed CEO submits application to FDA for Breakthrough Device Designation for innovative colorectal cancer screening product incorporating mRNA biomarkers. Strong clinical study results support the regulatory submission.

Mainz BioMed Seeks FDA Breakthrough Device Designation for Advanced Colorectal Cancer Test

This news matters as the Breakthrough Device Designation could accelerate the approval process for an innovative non-invasive colorectal cancer screening product, potentially benefiting early cancer detection efforts.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0xc1d0341a6a8ffe1609fc1f30524e90f10679753f5afbb1ee8f156269ff036dd2
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintcakeP3Tt-b33ba4149a6b3c49f62135a5dd3fdc8a